PolyNovo |
High $1.56 |
Low $1.52 |
Trades 1,747 |
Turnover $1,891,056 |
Volume 1,225,647 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (13-Nov) $618,303,552 (311th) |
Close (30-Jun) $1.55 |
Volume (30-Jun) 1,225,647 |
Shortsold (6-Nov) 46,180,514 (6.68%) (49th) |
|
52w High $1.30 |
52w Low $0.81 |
P/E 90.91 |
EPS 0.01 |
Chairman, Managing Director & SVP of Sales US - AGM address
PNV released this announcement to the ASX on 13 November 2020, 12:51. The announcement is marked as price sensitive, and is 6 page(s) in length and 241.23kb in size.
You can view all announcements from PNV and see how they appear on a price chart on the announcements page.
At the date of this announcement, PNV was 4.680% short sold according to ASIC data. It was ranked the 37th most shorted stock on the ASX. It remains ranked 49th as of the latest reported data (06 November 2026).
| Other Recent Announcements from PNV | |
|---|---|
| Appendix 3Y - Robyn Elliott | 30 June 2023, 10:41 |
| Director Share Purchase - David Williams | 8 June 2023, 15:14 |
| Director Share Purchase - David Williams | 8 June 2023, 8:19 |
| Chairman, Managing Director & SVP of Sales US - AGM address | 13 November 2020, 12:51 |
| USA FDA approves Pivotal Trial IDE | 13 November 2020, 10:30 |
| PolyNovo enters Greece - Distributor Appointment | 2 November 2020, 9:45 |
| Taiwan FDA Approval for PolyNovo | 28 October 2020, 9:11 |
If you were already registered, log in here.